Search Results
Search for other papers by Sonia M Abuzakhm in
Google Scholar
PubMed
Search for other papers by Vineeth Sukrithan in
Google Scholar
PubMed
Search for other papers by Briant Fruth in
Google Scholar
PubMed
Search for other papers by Rui Qin in
Google Scholar
PubMed
Search for other papers by Jonathan Strosberg in
Google Scholar
PubMed
Search for other papers by Timothy J Hobday in
Google Scholar
PubMed
Search for other papers by Thomas Semrad in
Google Scholar
PubMed
Search for other papers by Diane Reidy-Lagunes in
Google Scholar
PubMed
Search for other papers by Hedy Lee Kindler in
Google Scholar
PubMed
Search for other papers by George P Kim in
Google Scholar
PubMed
Search for other papers by Jennifer J Knox in
Google Scholar
PubMed
Search for other papers by Andreas Kaubisch in
Google Scholar
PubMed
Search for other papers by Miguel Villalona-Calero in
Google Scholar
PubMed
Search for other papers by Helen Chen in
Google Scholar
PubMed
Search for other papers by Charles Erlichman in
Google Scholar
PubMed
Search for other papers by Manisha H Shah in
Google Scholar
PubMed
tract (also referred to as carcinoid tumors) typically behave in an indolent fashion, while high-grade neuroendocrine tumors are aggressive. In patients with unresectable or metastatic extra-pancreatic NETs, options for treatment are limited. Lanreotide
Department of Diabetology, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Marc Diedisheim in
Google Scholar
PubMed
Department of Gastroenterology and Digestive Oncology, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Solène Dermine in
Google Scholar
PubMed
Department of Endocrinology, Center for Rare Adrenal Diseases, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Anne Jouinot in
Google Scholar
PubMed
Search for other papers by Amandine Septier in
Google Scholar
PubMed
Department of Digestive Surgery, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Sébastien Gaujoux in
Google Scholar
PubMed
Department of Digestive Surgery, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Bertrand Dousset in
Google Scholar
PubMed
Search for other papers by Guillaume Cadiot in
Google Scholar
PubMed
Department of Diabetology, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Etienne Larger in
Google Scholar
PubMed
Department of Endocrinology, Center for Rare Adrenal Diseases, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Jérôme Bertherat in
Google Scholar
PubMed
Search for other papers by Raphael Scharfmann in
Google Scholar
PubMed
Department of Pathology, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Benoit Terris in
Google Scholar
PubMed
Department of Gastroenterology and Digestive Oncology, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Romain Coriat in
Google Scholar
PubMed
Department of Endocrinology, Center for Rare Adrenal Diseases, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris, France
Search for other papers by Guillaume Assié in
Google Scholar
PubMed
represent this family of fibrinogen genes with highly correlated expression. In univariate analysis, high grade tumors (grade 2, grade 3 and neuroendocrine carcinomas) (HR = 11.83, P = 0.001) and FGA expression (HR = 1.13, P = 0.005) were associated
Search for other papers by Zane Hammoud in
Google Scholar
PubMed
Search for other papers by Bailin Tan in
Google Scholar
PubMed
Search for other papers by Sunil Badve in
Google Scholar
PubMed
Search for other papers by Robert M Bigsby in
Google Scholar
PubMed
, activating mutations in each of these signaling molecules have been shown to be more prevalent in lung adenocarcinomas found in women than in men ( Graziano et al . 1999 , Nelson et al . 1999 , Shigematsu & Gazdar 2006 ). A high percentage of human lung
Search for other papers by J Hadoux in
Google Scholar
PubMed
Search for other papers by D Malka in
Google Scholar
PubMed
Search for other papers by D Planchard in
Google Scholar
PubMed
Search for other papers by J Y Scoazec in
Google Scholar
PubMed
Search for other papers by C Caramella in
Google Scholar
PubMed
Search for other papers by J Guigay in
Google Scholar
PubMed
Search for other papers by V Boige in
Google Scholar
PubMed
Search for other papers by S Leboulleux in
Google Scholar
PubMed
Search for other papers by P Burtin in
Google Scholar
PubMed
Search for other papers by A Berdelou in
Google Scholar
PubMed
Search for other papers by Y Loriot in
Google Scholar
PubMed
Search for other papers by P Duvillard in
Google Scholar
PubMed
Search for other papers by C N Chougnet in
Google Scholar
PubMed
Search for other papers by D Déandréis in
Google Scholar
PubMed
Search for other papers by M Schlumberger in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Tumors, Digestive Oncology, Medical Oncology (Thoracic Group), Pathology, Radiology, Centre Antoine Lacassagne, Department of Urologic Oncology, Department of Endocrinology, Department of Biostatistics and Epidemiology, Faculté de Médecine, Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, France
Search for other papers by I Borget in
Google Scholar
PubMed
Departments of Nuclear Medicine and Endocrine Tumors, Digestive Oncology, Medical Oncology (Thoracic Group), Pathology, Radiology, Centre Antoine Lacassagne, Department of Urologic Oncology, Department of Endocrinology, Department of Biostatistics and Epidemiology, Faculté de Médecine, Gustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, France
Search for other papers by M Ducreux in
Google Scholar
PubMed
Search for other papers by E Baudin in
Google Scholar
PubMed
. 2010 , Panzuto et al . 2011 , Strosberg et al . 2011 ). These tumors, when located in the digestive system, are classified as WHO grade 3 NEC (G3-NEC), characterized by a poorly differentiated morphology, a mitotic count above 20/10 high-power field
Search for other papers by Mieke E R Henfling in
Google Scholar
PubMed
Search for other papers by Aurel A Perren in
Google Scholar
PubMed
Search for other papers by Anja M Schmitt in
Google Scholar
PubMed
Search for other papers by Christiane M Saddig in
Google Scholar
PubMed
Search for other papers by Achim A Starke in
Google Scholar
PubMed
Search for other papers by Robert G Riedl in
Google Scholar
PubMed
Search for other papers by Yvonne M H Versleijen-Jonkers in
Google Scholar
PubMed
Search for other papers by Diana M Sprij-Mooij in
Google Scholar
PubMed
Search for other papers by Frans C S Ramaekers in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
Search for other papers by Ernst-Jan M Speel in
Google Scholar
PubMed
, (A) IGF2 (moderate (2) vs high (3) expression), (B) cytoplasmic IGF1R (low vs high expression), (C) cytoplasmic INSR (low vs high expression), (D) Grade (Grade1 vs Grade 2 + 3), (E) Disease (non-metastatic vs metastatic), (F) Tumor size (<2 cm vs ≥2
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
Search for other papers by David P Ryan in
Google Scholar
PubMed
Search for other papers by Andrew X Zhu in
Google Scholar
PubMed
Search for other papers by Thomas A Abrams in
Google Scholar
PubMed
Search for other papers by Brian M Wolpin in
Google Scholar
PubMed
Search for other papers by Paige Malinowski in
Google Scholar
PubMed
Search for other papers by Eileen M Regan in
Google Scholar
PubMed
Search for other papers by Charles S Fuchs in
Google Scholar
PubMed
Search for other papers by Matthew H Kulke in
Google Scholar
PubMed
histologically documented, locally unresectable or metastatic carcinoid or pancreatic neuroendocrine tumors of low grade or intermediate histological grade. Patients with poorly differentiated or high-grade neuroendocrine carcinomas were not eligible. Treatment
Search for other papers by Mintallah Haider in
Google Scholar
PubMed
Search for other papers by Satya Das in
Google Scholar
PubMed
Search for other papers by Taymeyah Al-Toubah in
Google Scholar
PubMed
Search for other papers by Eleonora Pelle in
Google Scholar
PubMed
Search for other papers by Ghassan El-Haddad in
Google Scholar
PubMed
Search for other papers by Jonathan Strosberg in
Google Scholar
PubMed
not reached in the PRRT arm (hazard ratio (HR) for disease progression or death 0.21, 95% CI, 0.13–0.33; P < 0.001). Response rates were 3% in the high-dose octreotide arm and 18% in the PRRT arm ( P < 0.001). In this analysis, grade 3
Search for other papers by Claudio Festuccia in
Google Scholar
PubMed
Search for other papers by Giovanni Luca Gravina in
Google Scholar
PubMed
Search for other papers by Paola Muzi in
Google Scholar
PubMed
Search for other papers by Roberto Pomante in
Google Scholar
PubMed
Search for other papers by Luca Ventura in
Google Scholar
PubMed
Search for other papers by Robert L Vessella in
Google Scholar
PubMed
Search for other papers by Carlo Vicentini in
Google Scholar
PubMed
Search for other papers by Mauro Bologna in
Google Scholar
PubMed
moderate disorganization and a modest degree of stromal invasion (Gleason scores of 7); and group III consisted of poorly differentiated tumors showing high levels of disorganization and stromal invasion (Gleason of 8–10). Considering that the Gleason grade
Search for other papers by Anna Koumarianou in
Google Scholar
PubMed
Search for other papers by Stavroula Antoniou in
Google Scholar
PubMed
Search for other papers by George Kanakis in
Google Scholar
PubMed
Search for other papers by Nikolaos Economopoulos in
Google Scholar
PubMed
Search for other papers by Dimitra Rontogianni in
Google Scholar
PubMed
Search for other papers by Anastasios Ntavatzikos in
Google Scholar
PubMed
Search for other papers by Nikolaos Tsavaris in
Google Scholar
PubMed
Search for other papers by Dimitrios Pectasides in
Google Scholar
PubMed
Search for other papers by George Dimitriadis in
Google Scholar
PubMed
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Dear Editor Neuroendocrine tumours (NETs) are highly vascularised tumours that express high levels of the vascular endothelial growth factor (VEGF) ligand together with its receptor VEGFR ( Modlin et al . 2008 ). Although advanced NETs may exhibit
Search for other papers by Kimberly Kamp in
Google Scholar
PubMed
Search for other papers by Brenda Gumz in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Dik J Kwekkeboom in
Google Scholar
PubMed
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Search for other papers by Frederico P Costa in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
-differentiated (WHO grades 1 and 2) GEP-NETs with progressive disease (PD), with a well-established safety profile ( Yao et al . 2008 , 2010 , 2011 , Pavel et al . 2011 ). In the randomized phase III RADIANT-3 study, everolimus therapy was associated with a 2